NKGen Biotech, Inc. is a biotechnology company focused on developing innovative therapies that leverage the potential of natural killer (NK) cell technology for the treatment of various cancers and autoimmune diseases
The company is committed to advancing its proprietary platform, which aims to enhance the immune system's ability to identify and eradicate malignant cells. Through rigorous research and clinical development, NKGen Biotech seeks to provide novel treatment options that can improve patient outcomes and address unmet medical needs in the landscape of immunotherapy.
NKGen Biotech shares are trading higher by 32.5% Thursday morning. The company announced it will present new SNK01 biomarker data at the Alzheimer's Association International Conference.
